TScan Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in two upcoming investor conferences.

The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 5:35 p.m. ET, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9:00 a.m. ET. Both presentations will be available via webcast on the company's investor relations website for 90 days following the events.

WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

• Morgan Stanley 23^rd Annual Global Healthcare Conference; the fireside chat will be held at the Sheraton New York Times Square on Tuesday, September 9, 2025 at 5:35 p.m. ET
  
• H.C. Wainwright 27^th Annual Global Investment Conference; the presentation will be held at the Lotte New York Palace Hotel on Wednesday, September 10, 2025 at 9:00 a.m. ET
  

Webcasts of the fireside chat and presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. Archived replays of the webcasts will be available on the Company’s website for 90 days following the events.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA^™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T^™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Melissa Forst
Argot Partners
212-600-1902
TScan@argotpartners.com

FAQ

When is TScan Therapeutics (TCRX) presenting at the Morgan Stanley Healthcare Conference 2025?

TScan Therapeutics will present a fireside chat at the Morgan Stanley conference on September 9, 2025 at 5:35 p.m. ET at the Sheraton New York Times Square.

Where can I watch TScan Therapeutics' (TCRX) investor conference presentations?

The webcasts will be available in the 'Events and Presentations' section of TScan's website at ir.tscan.com, with replays available for 90 days after the events.

What type of company is TScan Therapeutics (TCRX)?

TScan Therapeutics is a clinical-stage biotechnology company that develops TCR-engineered T cell (TCR-T) therapies for cancer treatment.

Which investor conferences will TScan Therapeutics (TCRX) attend in September 2025?

TScan will attend the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025.